Skip to search formSkip to main contentSkip to account menu

TZP-101

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Introduction: Gastroparesis is an important clinical disorder characterised by delayed gastric emptying in the absence of… 
Highly Cited
2011
Highly Cited
2011
Aliment Pharmacol Ther 2011; 33: 679–688 
Highly Cited
2011
Highly Cited
2011
High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay… 
Highly Cited
2010
Highly Cited
2010
Background  Gastroparesis, a chronic disorder of abnormal gastric motility, is common in patients with diabetes mellitus. A… 
Highly Cited
2010
Highly Cited
2010
PURPOSE: Ghrelin agonist TZP-101 is a potent prokinetic. This phase 2b study evaluated TZP-101 safety and efficacy in… 
Highly Cited
2009
Highly Cited
2009
Background  TZP‐101 is a synthetic, selective ghrelin agonist in development for gastroparesis. 
2009
2009
AbstractBackground and objective: TZP-101 is a selective, small molecule ghrelin receptor agonist in clinical development for the… 
Highly Cited
2008
Highly Cited
2008
The authors evaluate the human safety, tolerability, pharmacokinetics, and pharmacodynamics of TZP‐101, an agonist of the hGHS… 
2008
2008
The peptide hormone ghrelin exerts a wide spectrum of activities including the stimulation of GH release, feeding, and… 
Highly Cited
2007
Highly Cited
2007
Postoperative ileus (POI) is a major cause of postoperative complications and prolonged hospitalization. Ghrelin, which is the…